EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First‐In‐Human Study Using Single and Multiple Ascending Doses

Nathalie Chauret, Denis Garceau, Laurent Harvey, Zelie Bailes, Elizabeth A Duncan, Rhian McNaughton, Miren Zamacona

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70253 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Nathalie Chauret und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bellus Health, Laval, Quebec, Canada. Hauptthemen laut MEDLINE: Purinergic P2X Receptor Antagonists. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bellus Health, a GSK company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Camlipixant is a highly selective P2X3 receptor antagonist with demonstrated efficacy in pre‐clinical models of evoked cough. We report the safety, tolerability, and pharmacokinetics of camlipixant in healthy participants. This Phase 1, double‐blind, randomized study evaluated single ascending doses (SAD; 50/100/200/400/800/1200 mg) and multiple ascending doses (MAD; 100/200/400 mg, twice daily [BID]) of oral camlipixant versus placebo. Ninety participants were included (SAD n = 60; MAD n = 30). Treatment‐emergent adverse event (TEAE) incidence was similar between camlipixant (32/72) and placebo (9/18). TEAEs were mostly mild (83%), and the most common with camlipixant was dysgeusia, primarily at doses ≥400 mg (n = 13), versus 50–200 mg (n = 1). Camlipixant was rapidly absorbed (time to maximum plasma concentration SAD: 0.77–2.29 h; MAD: 0.50–2.00 h), with a short half‐life (SAD 4.28–6.71 h; MAD 7.60–8.39 h). In both cohorts, maximum plasma concentration (C max ) increased proportionally with dose. The area under the curve extrapolated to infinity (AUC 0–∞ ) increased proportionally with dose in the SAD cohort; the increase was slightly supra‐proportional in the MAD cohort (steady state reached on Day 2). The geometric mean apparent volume of distribution ranged from 44.9 to 70.2 L and clearance from 5.7 to 10.4 L/h in the SAD cohort. Pharmacokinetics were unaffected by food (geometric mean fed/fasted ratio C max 91.4% [90% confidence interval, CI, 69.8–119.6]; AUC 0–∞ 105.5% [90% CI, 89.8–124.0]). In summary, camlipixant was well tolerated, with pharmacokinetics supporting BID dosing and further clinical development for refractory chronic cough.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purinergic P2X Receptor AntagonistsHumansFemaleMaleAdultDouble-Blind MethodAdministration, OralYoung AdultMiddle AgedDose-Response Relationship, DrugArea Under CurveAdolescentHalf-Life

Stichwörter der Autor:innen

P2X3 antagonistcamlipixantchronic coughpharmacokineticsrefractory chronic coughsafety

Substanzen

Purinergic P2X Receptor Antagonists

Autor:innen und Institutionen

  • Bellus Health, Laval, Quebec, Canada.
  • GSK, London, UK.
  • GSK, Durham, North Carolina, USA.

Förderung

  • Bellus Health, a GSK company

Zitieren

APA

Chauret, N., Garceau, D., Harvey, L., Bailes, Z., Duncan, E. A., McNaughton, R., & Zamacona, M. (2026). Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First‐In‐Human Study Using Single and Multiple Ascending Doses. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70253

Vancouver

Chauret N, Garceau D, Harvey L, Bailes Z, Duncan EA, McNaughton R, et al. Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First‐In‐Human Study Using Single and Multiple Ascending Doses. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70253

BibTeX
@article{Chauret2026,
  author = {Chauret, Nathalie and Garceau, Denis and Harvey, Laurent and Bailes, Zelie and Duncan, Elizabeth A and McNaughton, Rhian and Zamacona, Miren},
  title = {Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First‐In‐Human Study Using Single and Multiple Ascending Doses},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70253}
}
Kostenlos starten →